Hinshaw & Culbertson LLP today announced that Frank A. Mazzagatti has joined the firm's Health Care industry group as a partner in the New York office. Mazzagatti brings extensive experience with health care regulatory compliance, licensing matters, and transactions.

The law firm of Hinshaw & Culbertson LLP is pleased to announce that Scott Seaman—Chicago-based partner and co-chair of Hinshaw's global Insurance Services Practice Group—has been named a Top Author in the Insurance category of the 2024 JD Supra Readers' Choice Awards. This marks the fourth consecutive year Seaman was named a Top Insurance Author in the JD Supra Readers' Choice Awards. Honorees were selected from a pool of 2,600 insurance law authors.  

The U.S. law firm of Hinshaw & Culbertson LLP is pleased to announce that Hinshaw partner Michael Dowell has been recognized as a "Top Health Care Lawyer" in California by The Daily Journal. The list honors leading California attorneys who focus on health care litigation, transactions, and counseling, with honorees selected by Daily Journal editors from nominations submitted by lawyers statewide. The Los Angeles and San Francisco Daily Journals provide information on the legal industry, real estate and general business in California.

Read Michael Dowell’s BioXconomy interview, where he explains California SB 41 PBM reforms—rebate pass-throughs, fiduciary duties, and transparency—and offers practical compliance steps.

Read Hinshaw partner Michael Dowell's article in the October 2025 edition of the U.S. Pharmacist, which explores how telepharmacy and remote dispensing are being used to combat the rising number of pharmacy closures and pharmacy deserts in underserved urban and rural areas.

In a legal column published by U.S. Pharmacist, Hinshaw partner Michael Dowell discussed the impact of the U.S. Supreme Court's decision in the consolidated case Ruan v. United States and Kahn v. United States. The Ruan decision ruled that the Drug Enforcement Administration (DEA) must prove beyond a reasonable doubt that a prescriber knowingly or intentionally issued a prescription that they knew or intended was not for a legitimate medical purpose in order to subject that physician to criminal penalties under the Controlled Substances Act (CSA). 

Read our healthcare team’s alert for implementation guidance to prepare before the Illinois Medical Aid in Dying Act takes effect on September 12, 2026.

Read our latest alert on California’s SB 41 for a practical compliance roadmap—implementation timeline, immediate next steps, a 30-day action checklist, and ongoing planning guidance to align PBM practices by January 1, 2026.

Learn how OIG Advisory Opinion 25-03 safeguards and compliance best practices can help providers expand their telehealth services while minimizing regulatory risk.